Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

BUPIVACAINE LIPOSOME

BUPIVACAINE

Standard Dose
133MG/10ML (13.3MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview BUPIVACAINE LIPOSOME is listed in Drugs@FDA under application 214348 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient BUPIVACAINE Form and strength INJECTABLE, LIPOSOMAL;INJECTION - 133MG/10ML (13.3MG/ML) Sponsor HENGRUI PHARMA Submission history Latest submission status date: 2024-07-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview BUPIVACAINE LIPOSOME is listed in Drugs@FDA under application 214348 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BUPIVACAINE Form and strength INJECTABLE, LIPOSOMAL;INJECTION - 133MG/10ML (13.3MG/ML) Sponsor HENGRUI PHARMA Submission history Latest submission status date: 2024-07-01 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.